Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization (CTA) application to the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease). ALN-AAT02 is Alnylam's first investigational RNAi therapeutic utilizing the Company's enhanced stabilization chemistry plus (ESC+) GalNAc-conjugate technology.

"We are pleased to reignite our efforts to develop a treatment for alpha-1 liver disease, where there is high unmet need with liver transplantation as the only available treatment option," said Thomas Hoock, Ph.D., Vice President, Program Lead for ALN-AAT02 at Alnylam. "We are also excited for ALN-AAT02 to enter the clinic as the first investigational RNAi therapeutic that will leverage the significant enhancements we have made to our GalNAc-siRNA conjugate platform. Pending feedback from the MHRA, we look forward to evaluating the safety, pharmacodynamics, and clinical activity of this molecule in a Phase 1/2 study in healthy volunteers and adults with alpha-1 liver disease, which we expect to initiate by year-end 2018."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study sheds light on a potential new strategy to prevent fatty liver